Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QDEL 
Quidel Corporation (QDEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: QDEL (1-star) is a SELL. SELL since 2 days. Simulated Profits (-8.75%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $39.17
1 Year Target Price $39.17
| 3 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.56% | Avg. Invested days 30 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.79B USD | Price to earnings Ratio - | 1Y Target Price 39.17 |
Price to earnings Ratio - | 1Y Target Price 39.17 | ||
Volume (30-day avg) 8 | Beta 0.27 | 52 Weeks Range 22.05 - 49.45 | Updated Date 10/15/2025 |
52 Weeks Range 22.05 - 49.45 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -17.01% | Operating Margin (TTM) -0.73% |
Management Effectiveness
Return on Assets (TTM) 1.36% | Return on Equity (TTM) -15.64% |
Valuation
Trailing PE - | Forward PE 9.59 | Enterprise Value 4809061879 | Price to Sales(TTM) 0.65 |
Enterprise Value 4809061879 | Price to Sales(TTM) 0.65 | ||
Enterprise Value to Revenue 1.75 | Enterprise Value to EBITDA 22.78 | Shares Outstanding 67900466 | Shares Floating 62647686 |
Shares Outstanding 67900466 | Shares Floating 62647686 | ||
Percent Insiders 0.92 | Percent Institutions 117.22 |
Upturn AI SWOT
Quidel Corporation
Company Overview
History and Background
Founded in 1979, QuidelOrtho is a global provider of diagnostic healthcare solutions. It initially focused on developing rapid diagnostic tests and has expanded through organic growth and acquisitions.
Core Business Areas
- Point-of-Care (POC) Diagnostics: Develops and manufactures rapid diagnostic tests for infectious diseases, including influenza, COVID-19, RSV, and strep throat.
- Molecular Diagnostics: Offers molecular diagnostic solutions for detecting infectious diseases and other conditions.
- Immunoassay: Develops and manufactures assays for a wide range of clinical applications, including cardiac markers, women's health, and autoimmune diseases.
- Transfusion Medicine: Provides solutions for blood typing and screening.
Leadership and Structure
Douglas Bryant is the CEO. The company operates with a functional organizational structure, dividing operations into R&D, Manufacturing, Sales, and Marketing.
Top Products and Market Share
Key Offerings
- Sofia 2 Flu A+B FIA: A rapid influenza A and B antigen test. Competitors include Abbott, Roche, and BD. Market share varies regionally, with estimates ranging from 15-25% in the US for rapid flu tests prior to COVID-19. (Now, includes COVID testing).
- Lyra SARS-CoV-2 Assay: A PCR-based test for detecting SARS-CoV-2. Competitors include Roche, Thermo Fisher Scientific, and Abbott. COVID related products produced approximately $2.5 Billion in revenue in 2021 but has decreased substantially since.
- QuickVue Dipstick Strep A Test: A rapid antigen test for detecting Strep A. Competitors include BD and Beckman Coulter. Specific market share data is limited.
Market Dynamics
Industry Overview
The diagnostics industry is experiencing growth driven by technological advancements, aging populations, and increasing prevalence of chronic diseases. Point-of-care diagnostics and molecular diagnostics are key growth areas.
Positioning
QuidelOrtho is a significant player in the diagnostics market, particularly in point-of-care testing. Its competitive advantage lies in its established brand, rapid test development capabilities, and extensive distribution network.
Total Addressable Market (TAM)
The global diagnostics market is estimated at hundreds of billions of dollars. QuidelOrtho is well-positioned to capture a significant portion of this TAM, particularly in the infectious disease and point-of-care segments.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in point-of-care diagnostics
- Established distribution network
- Rapid test development capabilities
- Diverse product portfolio
- Presence in both POC and Molecular Diagnostics
Weaknesses
- Reliance on seasonal infectious disease testing
- Fluctuations in revenue based on pandemic trends
- Competition from larger, more diversified companies
- Historically, weaker international presence compared to competitors
Opportunities
- Expansion into emerging markets
- Development of new diagnostic tests for chronic diseases
- Strategic acquisitions to broaden product portfolio
- Increased adoption of point-of-care testing
- Leveraging data analytics for personalized medicine
Threats
- Intense competition in the diagnostics market
- Changing regulatory landscape
- Reimbursement pressures from healthcare providers
- Emergence of new infectious diseases that disrupt market demand
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- Abbott (ABT)
- Roche Holding AG (RHHBY)
- Becton, Dickinson and Company (BDX)
Competitive Landscape
QuidelOrtho competes with larger, more diversified companies. It differentiates itself through its focus on point-of-care diagnostics and rapid test development.
Major Acquisitions
Ortho Clinical Diagnostics
- Year: 2022
- Acquisition Price (USD millions): 6000
- Strategic Rationale: Expanded product portfolio into immunoassay and transfusion medicine, increased global presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by rapid test development and acquisitions.
Future Projections: Future growth depends on innovation, expanding into new markets, and potentially new respiratory illness surges.
Recent Initiatives: Focus on new product development (e.g., multiplex assays), strategic acquisitions, and expansion into international markets.
Summary
QuidelOrtho is a player in diagnostics, particularly in point-of-care. The company has seen volatility in recent years due to the effects of COVID-19 which produced extremely high revenues that have since decreased. Strengths include rapid test development and established distribution, whereas weaknesses are dependence on seasonal illnesses and competition. QuidelOrtho must continue to innovate and diversify its product portfolio to sustain growth in a competitive market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quidel Corporation
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 1991-02-01 | President, CEO & Director Mr. Brian J. Blaser | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6600 | Website https://www.quidelortho.com |
Full time employees 6600 | Website https://www.quidelortho.com | ||
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.